<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771702</url>
  </required_header>
  <id_info>
    <org_study_id>Edmon-Oslo-Low Back Surgery</org_study_id>
    <nct_id>NCT04771702</nct_id>
  </id_info>
  <brief_title>Expired Propofol in Low Back Surgery</brief_title>
  <official_title>Propofol Measurement in Expiration Air and Monitoring of EEG and Pain in Patients Undergoing Low Back Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Edmon (BBraun, Germany) is a portable, commercially available device for measurement of&#xD;
      propofol in exhaled air.&#xD;
&#xD;
      The study will aim at evaluating the sensitivity and specificity of such exhaled propofol&#xD;
      values compared with plasma propofol and measures of anaesthetic and antinociceptive effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elective low-back surgery patients will be induced for general intubation anesthesia with&#xD;
      propofol and remifentanil.&#xD;
&#xD;
      After induction a 20 min period of stable propofol infusion only will be established before&#xD;
      start of surgery. The patients will be monitored for exhaled propofol, plasma propofol (blood&#xD;
      samples), continous frontal EEG, Bispectral Index (BIS), skin conductance, estimated&#xD;
      (computer based) concentrations of plasma and effect site propofol, and skin conductance.&#xD;
&#xD;
      After start of surgery (with ongoing propofol and restart of remifentanil TCI) the monitoring&#xD;
      will continue in order to explore these relationships further.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The intervention is to have patients in 20 min stable anaesthesia before start of surgery in order to validate the use of exhaled propofol versus pharmakokinetic modelling and measured plasma concentration</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled air versus plasma concentration</measure>
    <time_frame>per-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG recording</measure>
    <time_frame>per-operative</time_frame>
    <description>EEG will be recorded and compared with plasma propofol, exhaled propofol and BIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled propofol 2</measure>
    <time_frame>per-operative</time_frame>
    <description>Exhaled propofol versus dose given, estimated plasma concentration, estimated effect site concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nociceptive stimulation</measure>
    <time_frame>per-operative</time_frame>
    <description>Skin conductance versus plasma and exhaled propofol concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Edmon arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edmon</intervention_name>
    <description>Exhaled air will be analyzed for propofol</description>
    <arm_group_label>Edmon arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective patients scheduled for low-back surgery&#xD;
&#xD;
          -  BMI between 20 -32 kg/m2&#xD;
&#xD;
          -  ASA I-II&#xD;
&#xD;
          -  Written informed concent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to propofol TCI&#xD;
&#xD;
          -  Use of psychopharmaco or neurologic disease&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin S Thagaard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan Raeder, PhD</last_name>
    <phone>004792249669</phone>
    <email>johan.rader@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Torsten Eken, PhD</last_name>
    <phone>004795079939</phone>
    <email>torsten.eken@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Anesthesiology, Oslo University Hospital, Ullevaal</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Raeder</last_name>
      <phone>+47 92249669</phone>
      <email>johan.rader@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Johan Raeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Johan C RÃ¦der</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

